Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NextCure ( (NXTC) ) has provided an announcement.
NextCure, Inc. is making strides in the financial markets with its new Investigational New Drug Application for LNCB74, targeting breast, endometrial, and ovarian cancers. This innovative antibody-drug conjugate employs a unique glucuronidase linker for enhanced safety and efficacy. With promising preclinical results and a strategic collaboration with LegoChemBio, the company is poised to initiate Phase 1 trials in early 2025, potentially offering a significant investment opportunity for those interested in groundbreaking cancer therapies.
For an in-depth examination of NXTC stock, go to TipRanks’ Stock Analysis page.